Literature DB >> 25135779

Managing the risks of ADHD treatments.

Benjamin N Schneider1, Michael Enenbach.   

Abstract

Pharmacotherapy of attention deficit-hyperactivity disorder (ADHD) is a well-established and effective treatment modality. However, ADHD medications are not without side effects. Understanding the prevalence of adverse events and effective management of risks associated with stimulants and other medications used to treat ADHD is central to broad applicability and effective treatment. This review discusses the literature on the prevalence of adverse events and management strategies employed. We searched online MEDLINE/PubMed and Cochrane databases for articles using several keywords relating to adverse events associated with ADHD medication management. We discuss the relevant data on the significance and prevalence of side effects and adverse events, highlight recent updates in the field, and suggest approaches to clinical management.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25135779     DOI： 10.1007/s11920-014-0479-3

Source DB:  PubMed          Journal:  Curr Psychiatry Rep        ISSN： 1523-3812            Impact factor:   5.285


  58 in total

1.  American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008.

Authors: 
Journal:  J Dev Behav Pediatr       Date:  2008-08       Impact factor: 2.225

2.  Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children.

Authors:  Robert L Findling; Joseph Biederman; Timothy E Wilens; Thomas J Spencer; James J McGough; Frank A Lopez; Simon J Tulloch
Journal:  J Pediatr       Date:  2005-09       Impact factor: 4.406

Review 3.  Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature.

Authors:  Samuele Cortese; Eric Konofal; Michel Lecendreux; Isabelle Arnulf; Marie-Christine Mouren; Francesca Darra; Bernardo Dalla Bernardina
Journal:  Sleep       Date:  2005-08-01       Impact factor: 5.849

Review 4.  First-onset tics in patients with attention-deficit-hyperactivity disorder: impact of stimulants.

Authors:  Veit Roessner; Monika Robatzek; Guido Knapp; Tobias Banaschewski; Aribert Rothenberger
Journal:  Dev Med Child Neurol       Date:  2006-07       Impact factor: 5.449

Review 5.  Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.

Authors:  Samuele Cortese; Martin Holtmann; Tobias Banaschewski; Jan Buitelaar; David Coghill; Marina Danckaerts; Ralf W Dittmann; John Graham; Eric Taylor; Joseph Sergeant
Journal:  J Child Psychol Psychiatry       Date:  2013-01-07       Impact factor: 8.982

Review 6.  Attention deficit/hyperactivity disorder and methylphenidate. A review of height/weight, cardiovascular, and somatic complaint side effects.

Authors:  Mark D Rapport; Catherine Moffitt
Journal:  Clin Psychol Rev       Date:  2002-11

Review 7.  Prospective association of childhood attention-deficit/hyperactivity disorder (ADHD) and substance use and abuse/dependence: a meta-analytic review.

Authors:  Steve S Lee; Kathryn L Humphreys; Kate Flory; Rebecca Liu; Kerrie Glass
Journal:  Clin Psychol Rev       Date:  2011-01-20

8.  Adolescent substance use in the multimodal treatment study of attention-deficit/hyperactivity disorder (ADHD) (MTA) as a function of childhood ADHD, random assignment to childhood treatments, and subsequent medication.

Authors:  Brooke S G Molina; Stephen P Hinshaw; L Eugene Arnold; James M Swanson; William E Pelham; Lily Hechtman; Betsy Hoza; Jeffery N Epstein; Timothy Wigal; Howard B Abikoff; Laurence L Greenhill; Peter S Jensen; Karen C Wells; Benedetto Vitiello; Robert D Gibbons; Andrea Howard; Patricia R Houck; Kwan Hur; Bo Lu; Sue Marcus
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2013-02-08       Impact factor: 8.829

9.  Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders.

Authors:  Michael H Bloch; Kaitlyn E Panza; Angeli Landeros-Weisenberger; James F Leckman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-09       Impact factor: 8.829

10.  Clonidine for attention-deficit/hyperactivity disorder: II. ECG changes and adverse events analysis.

Authors:  W Burleson Daviss; Nick C Patel; Adelaide S Robb; Michael P McDERMOTT; Oscar G Bukstein; William E Pelham; Donna Palumbo; Peter Harris; Floyd R Sallee
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-02       Impact factor: 8.829
View more
  5 in total

Review 1.  Use of Stimulants in Bipolar Disorder.

Authors:  Giulio Perugi; Giulia Vannucchi; Fulvio Bedani; Ettore Favaretto
Journal:  Curr Psychiatry Rep       Date:  2017-01       Impact factor: 5.285

2.  Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.

Authors:  Samuele Cortese; Pietro Panei; Romano Arcieri; Elena A P Germinario; Annalisa Capuano; Lucia Margari; Flavia Chiarotti; Paolo Curatolo
Journal:  CNS Drugs       Date:  2015       Impact factor: 5.749

3.  Managing the comorbidity of schizophrenia and ADHD.

Authors:  Amy Gough; Jason Morrison
Journal:  J Psychiatry Neurosci       Date:  2016-08       Impact factor: 6.186

4.  The Role of Animal Assisted Intervention on Improving Self-Esteem in Children With Attention Deficit/Hyperactivity Disorder.

Authors:  Sabrina E B Schuck; Heather L Johnson; Maryam M Abdullah; Annamarie Stehli; Aubrey H Fine; Kimberley D Lakes
Journal:  Front Pediatr       Date:  2018-11-02       Impact factor: 3.418

Review 5.  Practitioner's review: medication for children and adolescents with autism spectrum disorder (ASD) and comorbid conditions.

Authors:  Christian Popow; Susanne Ohmann; Paul Plener
Journal:  Neuropsychiatr       Date:  2021-06-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.